Patients in poorer countries often have to wait a number of years until the patents expire on new drugs and can be made more cheaply by generic companies. This week however, Gilead Sciences has struck a deal with Mylan Inc. to allow four of its AIDS drugs to be made generic at an obviously cheaper cost in return for a small percentage of royalties according to the United Nations. The first of its kind deal was negotiated by the U.N. led Medicines Patent Pool, a partnership that raises money for AIDS, tuberculosis and malaria...



Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/RAjac3XNdgw/230922.php
sport news news auto sport
No comments:
Post a Comment